Clinical Trial ECOG 3612
- A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
- Principal Investigator
- Sunandana Chandra
- Status: CLOSED
- Study Type: Therapeutic, Treatment
- Protocol No:.ECOG 3612
- The purpose of this research study is to compare the effects, good and/or bad, of ipilimumab or in combination with bevacizumab in treating unresectable advanced melanoma.
- Ipilimumab is the standard treatment for advanced melanoma and it does a good job in treating melanoma (skin cancer). Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is approved by the U.S. Food & Drug Adminstration(FDA)for treatment of other cancers but it's use in this study is experiment. This study is looking to see if the addition of bevacizumab to ipilimumab can further improve treament of melanoma.
Some of the eligibility criteria include:
- Particpants must be 18 years of age or older.
- Participants must have unresectable (can't be removed surgically) advanced melanoma that has not been treated or has only received one treatment.
- Description of Treatment
- There are two groups in this study, Group 1 and Group 2. Participants are randomized (like flipping a coin) into group 1 or 2. Both groups will receive ipilimumab for 3 months which is also referred to as a cycle. Group 2 will also take bevacizumab every 3 weeks. Participants will continue on this study until their disease progresses or the study doctor thinks it is in their best interest to continue.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Sunandana Chandra
- A Prospective, Randomized, Blinded, Placebocontrolled, Phase IIb Trial of an Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC In Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence
- A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
- Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV melanoma
- A Phase 2 Study of CDX-011 (glembatumumab vedotin) for Metastatic Uveal Melanoma
- A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
last updated: 24-Mar-17 10:55 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.